Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/7359
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBroto, Geise Ellen-
dc.contributor.authorCorrêa, Stephany Cristiane-
dc.contributor.authorTrigo, Fausto Celso-
dc.contributor.authorSantos, Everton Cruz dos-
dc.contributor.authorTomiotto-Pelissier, Fernanda-
dc.contributor.authorPavanelli, Wander Roge´rio-
dc.contributor.authorSilveira, Guilherme Ferreira-
dc.contributor.authorAbdelhay, Eliana Saul Furquim Werneck-
dc.contributor.authorPanis, Carolina-
dc.date.accessioned2022-06-09T18:00:36Z-
dc.date.available2022-06-09T18:00:36Z-
dc.date.issued2020-
dc.identifier.issn2234-943X-
dc.identifier.other10.3389/fonc.2020.550213-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/7359-
dc.description.abstractAmong the childhood diseases, B-cell acute lymphocytic leukemia (B-ALL) is the most frequent type of cancer. Despite recent advances concerning disease treatment, cytotoxic chemotherapy remains the first line of treatment in several countries, and the modifications induced by such drugs in the organism are still poorly understood. In this context, the present study provided a comparative high-throughput proteomic analysis of the cumulative changes induced by chemotherapeutic drugs used in the induction phase of B-ALL treatment in both peripheral blood (PB) and bone marrow compartment (BM) samples. To reach this goal, PB and BM plasma samples were comparatively analyzed by using label-free proteomics at two endpoints: at diagnosis (D0) and the end of the cumulative induction phase treatment (D28). Proteomic data was available via ProteomeXchange with identifier PXD021584. The resulting differentially expressed proteins were explored by bioinformatics approaches aiming to identify the main gene ontology processes, pathways, and transcription factors altered by chemotherapy, as well as to understand B-ALL biology in each compartment at D0. At D0, PB was characterized as a pro-inflammatory environment, with the involvement of several downregulated coagulation proteins as KNG, plasmin, and plasminogen. D28 was characterized predominantly by immune response-related processes and the super expression of the transcription factor IRF3 and transthyretin. RUNX1 was pointed out as a common transcription factor found in both D0 and D28. We chose to validate the proteins transthyretin and interferon-gamma (IFN-g) by commercial kits and expressed the results as PB/BM ratios. Transthyretin ratio was augmented after induction chemotherapy, while IFN-g was reduced at the end of the treatment. Considering that most of these proteins were not yet described in B-ALL literature, these findings added to understanding disease biology at diagnosis and highlighted a possible role for transthyretin and IFN-g as mechanisms related to disease resolution.pt_BR
dc.language.isoenpt_BR
dc.publisherFrontiers in Oncologypt_BR
dc.subjectInterferon-gammapt_BR
dc.subjectInterferon gamapt_BR
dc.subjectInterferón gammapt_BR
dc.subjectInterferon Regulatory Factor-3pt_BR
dc.subjectFator Regulador 3 de Interferonpt_BR
dc.titleComparative Analysis of Systemic and Tumor Microenvironment Proteomes From Children With B-Cell Acute Lymphocytic Leukemia at Diagnosis and After Induction Treatmentpt_BR
dc.TypeArticlept_BR
Appears in Collections:Artigo de Periódicos da Pesquisa Clínica



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.